Teva sells remaining women's health assets

18 September 2017

Israel’s Teva Pharmaceutical Industries (NYSE: TEVA) has entered into two agreements to sell the remaining assets of its specialty global women's health business for $1.38 billion, thus confirming the company’s previously-announced intention to divest these products.

Proceeds from these sales, combined with those from the recently announced sale of Paragard total $2.48 billion and will be used by Teva to progress repayment of term loan debt.

CVC Capital Partners Fund VI will acquire a portfolio of products within Teva’s global women's health business across contraception, fertility, menopause and osteoporosis for $703 million in cash. The portfolio of products, which is marketed and sold outside of the USA, includes the Ovaleap, Zoely, Seasonique, Colpotrophine and Actonel brands, and additional products. Combined annual net sales of these brands and additional products within this portfolio for the full year 2016 were $258 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK